We have received and recorded many benefits related to a wide variety of medical conditions. We only share some of them publicly for regulatory reasons. Our products are the subject of various ongoing human clinical trials seeking clearance by the U.S. Food and Drug Administration (FDA) and other health authorities around the world for a variety of chronic and acute health conditions.
Please contact us and share your experience and results. We are excited to inform people about the great benefits of using D’OXYVA®.
“Disseminated intravascular coagulation (DIC) is one of the severe complications related to COVID-19. This is a serious disorder in which the proteins that control blood clotting become overactive, which can result in symmetrical peripheral gangrene. Circularity’s D’OXYVA is a novel transdermal delivery system that can deliver carbon dioxide directly to body tissues low in oxygen. Further studies are needed, but this device has the potential to prevent symmetrical peripheral gangrene, a limb-threatening complication of COVID-19.”
”Toriyama et al. studied the effect of CO2 bathing in 83 limbs with critical ischemia and achieved limb salvage in 83% without surgery. They concluded that peripheral vasodilation from CO2 bathing resulted from an increased parasympathetic and decreased sympathetic activity. Application of transdermal CO2 produces a remote vasodilation that may be mediated through release of a circulating humoral agent.
Recently, studies have documented that episodes of brief, non-damaging ischemia occurring in a tissue can induce systemic protection against ischemia-reperfusion injury in a remote organ. This phenomenon, termed remote ischemic conditioning, has been demonstrated to confer protection against ischemic events in the myocardium, brain, and kidney. Although shown to be effective in various clinical and pre-clinical models, the mechanism(s) of remote protection have not been clearly identified.
Both neural and humoral mechanisms have been proposed to contribute to the protection against ischemic damage afforded by remote ischemic conditioning. Basalay et al. have shown that when remote ischemic conditioning is applied before induction of myocardial ischemia, sensory nerves and recruitment of a parasympathetic neural pathway are involved in reduction of infarct size. Recently, Michelsen and colleagues have demonstrated that dialysate of human plasma from subjects who underwent either ischemic preconditioning or exercise preconditioning reduced infarct size in rabbit hearts, indicating that release of a humoral factor, contributes to the cardioprotective effects of ischemic and exercise preconditioning; however, these circulating substance(s) remain to be identified.
Future investigations will need to monitor heart rate, heart rate variability, and sympathetic nerve activity in order to more fully assess the role of the autonomic nervous system in mediating the sustained increases in SPP and systolic blood pressure reported in this initial study and focus on assessment of plasma samples during and following transdermal CO2 application. The D’OXYVA device is safe and can be administered at home. There are a lot of possibilities here and we are really excited about conducting future studies to determine what D’OXYVA may be able to provide to people with microvascular disease.”
”In every 30 seconds a diabetic lower limb is lost somewhere in the world. For this reason diabetes and wounds is a dangerous combination; therefore, the management can be difficult. The standard treatment of a diabetic wound includes accurate surgical debridement and controlling the diabetic metabolism, as well as eliminating the infection by means of antibiotic therapy. In our presented case an insulin-dependent diabetic patient was treated for trimalleolar ankle fracture combined with very serious soft tissue destruction.
After admission to our department the possible treatment options were amputation or a long-term combined surgical treatment. The patient underwent a very drastic surgical debridement, the necrotised skin was removed. Infection was diagnosed with the identified pathogens being Enterobacter cloacae and ludwigii, Acinetobacter sp., Proteus mirabilis and Escherichia coli. After microbiological consultation an adequate antibiotic treatment was introduced. Every two days we repeated the surgical debridement and we applied jet lavage. After ten days there were no further necrotised tissue so we continued with a VAC therapy for two weeks. With the assistance of a plastic surgeon we applied Integra® and after a few days a split-thickness skin graft. Patient’s compliance dropped off and needed psychological support. During episodes of confusion he removed the dressings and surprisingly after two weeks fly larvae (Diptera: Sarcophagidae) were found in the skin grafted area.
Then wound healing was accelerated by Bioptron® light therapy and D’OXYVA® (deoxyhemoglobin vasodilator) treatment was applied twice a day for 25 days. His wound nearly completely healed and closed after 25 days and he could walk with crutches. He was discharged home after three months of treatment.
CONCLUSION: Even a serious soft tissue damage can heal after applying adequate therapy, but in diabetic patients the decision is difficult. It is important to note that in order to avoid amputation, multidisciplinary approach is mandatory. The patient’s general condition, life expectancy, and compliance basically influence our decisions and during the treatment period we have to reassess the results and taking these factors into account, thus we can choose the best treatment option.”
“The results were pretty astonishing, there was a 6% increase in capillary length (meaning more blood-filled capillaries) and a 14% increase in capillary diameter measuring results with MicroScan after just a few minutes of a single 5-minute (16g CO2) application. The results are more pronounced when considering small vessels (< 20 microns), which include the capillaries. Our early tests suggest D’OXYVA significantly improves blood circulation in the tiniest vessels and more profoundly in people with imbalances in their body than young healthy people.
We are proposing a clinical trial for rheumatoid arthritis patients where we expect significant pain reduction coupled with equally significant circulation improvements in just a month.”
”It works well, proven by the improvement of the perfusion index (PI-Masimo) of the diabetic wounds of Grade Wagner-I and Wagner-2 after a series of 5 applications. We continued the work by measuring TcPO2 (SENTEC) in another group of 15 patients with the same protocol, whereby we can prove that the transdermal CO2 application of D’OXYVA results in wound treatment improvement.”
”I have been using the D’OXYVA for past 4 years. After I started using the D’OXYVA, I felt a major improvement in my breathing because my sinus issues had cleared up. Second, I stopped snoring. After about 4 months, I realized that my muscles felt better and I was gaining my muscle mass back.
Then, I realized the varicose veins in my ankles had been reduced to less than 1/3 of it was. I have had a major reduction in pain and inflammation throughout my body. Now 4 years later, I feel physically stronger than I did 20 years ago. I am still increasing my muscle mass just by daily stretching, deep breathing and doing a D’OXYVA application three times weekly. I know that the D’OXYVA applications have caused my body to feel good again.
I have clients that have had similar and various results. One client has reported a major improvement in their eyesight. Six different clients have reported a reduction of varicose veins. A lot of clients have reported reduced amounts of inflammation and pain. Some clients have reported an increase in energy and endurance.
The fact is that the D’OXYVA increases the effectiveness of the Microcirculatory System. The body will feel better because of Microcirculatory System will improve the blood flow throughout the body. Increasing the blood flow will help the body heal itself.
I can highly recommend everyone should be doing D’OXYVA applications on a regular basis. You will be able to feel the difference.”
”At European Dermatology London we use the D’OXYVA device after non-surgical aesthetic procedures to help reduce the down-time for patients; and as part of our Medical-grade Pedicures for diabetic patients, who often suffer with impairments in their feet’s microcirculation.”
”Circularity has a novel, affordable treatment for patients. The D’OXYVA delivery system can be purchased by the patient and they have it in their homes for the rest of their lives. They can then treat pets and family members with a 7 minute treatment per day for about the same daily cost as a Starbucks coffee. The cumulative benefits of using D’OXYVA daily are immeasurable in so many health conditions.
My experience with patients in my Functional medicine practice was that 7/10 patients felt an immediate calming effect after one treatment. We documented most patients had a five point drop in blood pressure and pulse decrease within five minutes of one treatment. I am intrigued with the new data physicians will be presented with the clinics’ diagnostic platform. However, most doctors will have few treatment options to suggest other than diet and exercise and nutraceuticals.
Physicians who adopt D’OXYVA will be able to offer their patients with a novel, effective, affordable way to address these imbalances. And they can be delivered in the comfort of their own home. This is the perfect storm!”
Circularity Healthcare Announces Expansion with Global CRO of Series of Successful Pivotal Human Clinical Trials to Study Use of D’OXYVA® for Rapid, Economical and Noninvasive Home Treatment of Diabetic Foot Ulcers (DFU)
PASADENA, Calif., Feb. 1, 2021 5:31 AM PST (MORNINGSTAR) Addressing urgent and increased DFU problem related to pandemic lockdowns. Circularity Healthcare announced it had successfully executed a contract with the
LOS ANGELES (PRWEB) DECEMBER 11, 2019 Circularity is partnering with Telly Award-Winning “Behind the Scenes” to provide regular, ongoing, high-quality content from leading experts in a variety of fields with an
Switch To D'OXYVA®.
The only gentle, rapid, and painless transdermal solution without breaking the layers of the skin.
D’OXYVA® (deoxyhemoglobin vasodilator) biotechnology provides an inexpensive, simple and effective method of mild to severe chronic wound care. Its fully noninvasive transdermal approach delivers a host of benefits including but not limited to significant blood flow in the microcirculation (perfusion index), oxygen saturation (SpO2), nutrients, nerve stimulation (parasympathetic), which together are crucial for the complete and painless wound healing process.
Get in touch to avail D’OXYVA® for rapid chronic wound treatment.